Parkev Tatevosian, CFA发布 2026-09-26
《Novo Nordisk Gives Uninspiring Outlook》
$NVO看涨
尽管估值与信心有所下调，NVO 仍值得买入，仍有显著上行空间。
诺和诺德向投资者表示，到2030年公司将实现中个位数的收入增长。公司还表示，将把所服务的患者人数从目前的约4650万提升至6000万以上。
Novo Nordisk informed investors that it will increase its revenue at a medium single-digit rate through 2030. It also stated that it will increase the number of patients it serves to more than 60 million, up from about 46.5 million currently.
尽管预期强劲，投资者对诺和诺德的表现并不买账。自2026年初以来，该股已下跌超过25%。那么，这一切是否让诺和诺德在股价下跌时成为一个买入机会？
Despite these strong expectations, investors were not impressed with Novo Nordisk's performance. The stock has fallen by more than 25% since the beginning of 2026. So, does all this make Novo a buying opportunity when its price drops?
